Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial

NCT ID: NCT00465270

Last Updated: 2019-02-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

980 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-08-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate whether percutaneous Patent Foramen Ovale (PFO) closure, using the AMPLATZER PFO Occluder, is superior to current standard of care medical treatment in the prevention of recurrent embolic stroke.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The AMPLATZER PFO Occluder is a percutaneous, transcatheter occlusion device intended for the non-surgical closure of patent foramen ovale in subjects who have had a cryptogenic stroke due to presumed paradoxical embolism within the last 270 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cryptogenic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

AMPLATZER PFO Occluder
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Device

AMPLATZER PFO Occluder

Group Type EXPERIMENTAL

AMPLATZER PFO Occluder

Intervention Type DEVICE

patent foramen ovale closure device

Standard or Care - Medical Management

Medical treatment with Aspirin alone, Coumadin alone, Clopidogrel alone, or Aspirin combined with dipyridamole.

Group Type ACTIVE_COMPARATOR

Standard of Care - Medical Management

Intervention Type OTHER

Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMPLATZER PFO Occluder

patent foramen ovale closure device

Intervention Type DEVICE

Standard of Care - Medical Management

Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who have had a cryptogenic stroke within the last 270 days
* Subjects who have been diagnosed with a Patent Foramen Ovale (PFO)
* Subjects willing to participate in follow-up visits

Exclusion Criteria

* Subjects with intracardiac thrombus or tumor
* Subjects who have an acute or recent (within 6 months) myocardial infarction or unstable angina
* Subjects with left ventricular aneurysm or akinesis
* Subjects with atrial fibrillation/atrial flutter (chronic or intermittent)
* Subjects with another source of right to left shunt identified at baseline, including an atrial septal defect and/or fenestrated septum
* Subjects with contraindication to aspirin or Clopidogrel therapy
* Pregnant or desire to become pregnant within the next year
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffrey Saver, MD

Role: PRINCIPAL_INVESTIGATOR

UCLA Stroke Center

John D Carroll, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Richard Smalling, MD

Role: PRINCIPAL_INVESTIGATOR

University of Texas Houston Health Science Center

David Thaler, MD

Role: PRINCIPAL_INVESTIGATOR

Tufts Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama

Birmingham, Alabama, United States

Site Status

Mayo Clinic

Scottsdale, Arizona, United States

Site Status

LAC + USC Medical Center

Los Angeles, California, United States

Site Status

UCLA

Los Angeles, California, United States

Site Status

Summit Medical Center

Oakland, California, United States

Site Status

Sharp Memorial Hospital

San Diego, California, United States

Site Status

Kaiser Permanente

San Francisco, California, United States

Site Status

University of Colorado

Denver, Colorado, United States

Site Status

South Denver Cardiology Associates

Littleton, Colorado, United States

Site Status

Medical Center of the Rockies

Loveland, Colorado, United States

Site Status

Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

George Washington University Hospital

Washington D.C., District of Columbia, United States

Site Status

St. Vincent's Medical Center

Jacksonville, Florida, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

Neurologic Associates Inc

Palos Heights, Illinois, United States

Site Status

OSF St. Francis Medical Center

Peoria, Illinois, United States

Site Status

Southern Illinois University Neurology

Springfield, Illinois, United States

Site Status

Indiana Heart Physicians

Indianapolis, Indiana, United States

Site Status

Ruan Neurology

Des Moines, Iowa, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

Kansas University Medical Center

Kansas City, Kansas, United States

Site Status

University of Kentucky

Lexington, Kentucky, United States

Site Status

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Site Status

Midatlantic Cardiovascular Associates

Towson, Maryland, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

University of Michigan Health System

Ann Arbor, Michigan, United States

Site Status

St. Mary's Duluth Clinic

Duluth, Minnesota, United States

Site Status

Abbott Northwestern Hospital

Minneapolis, Minnesota, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Methodist Hospital/Park Nicollet Medical Center

Saint Louis Park, Minnesota, United States

Site Status

Washington University

St Louis, Missouri, United States

Site Status

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Our Lady of Lourdes Medical Center

Cherry Hill, New Jersey, United States

Site Status

University of Medicine and Dentistry of New Jersy

Newark, New Jersey, United States

Site Status

Albany Medical Center

Albany, New York, United States

Site Status

DENT Neurologic Institute

Amherst, New York, United States

Site Status

University of Rochester

Rochester, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Moses H. Cone Memorial Hospital

Greensboro, North Carolina, United States

Site Status

Neurology and Neuroscience Associates

Akron, Ohio, United States

Site Status

University Hospitals of Cleveland

Cleveland, Ohio, United States

Site Status

Ohio State University

Columbus, Ohio, United States

Site Status

Providence St. Vincent's Medical Center

Portland, Oregon, United States

Site Status

Oregon Stroke Center, OHSU

Portland, Oregon, United States

Site Status

LeHigh Valley Hospital

Allentown, Pennsylvania, United States

Site Status

Penn State Milton South Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Lancaster General Hospital

Lancaster, Pennsylvania, United States

Site Status

St. Mary's Medical Center

Langhorne, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

North Central Heart Institute

Sioux Falls, South Dakota, United States

Site Status

St. Thomas Neurology

Nashville, Tennessee, United States

Site Status

Vanderbilt University

Nashville, Tennessee, United States

Site Status

UT Southwestern Medical School

Dallas, Texas, United States

Site Status

University of Texas Houston Health Science Center

Houston, Texas, United States

Site Status

Sentara Virginia Beach General Hospital

Virginia Beach, Virginia, United States

Site Status

UW Medicine Stroke Center

Seattle, Washington, United States

Site Status

Charleston Area Medical Center

Charleston, West Virginia, United States

Site Status

University of Wisconsin Hospital

Madison, Wisconsin, United States

Site Status

Marshfield Clinic

Marshfield, Wisconsin, United States

Site Status

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

University of Alberta

Edmonton, Alberta, Canada

Site Status

Royal Columbian Hospital

New Westminster, British Columbia, Canada

Site Status

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status

St. Paul's Hospital

Vancouver, British Columbia, Canada

Site Status

Stroke Prevention & Atherosclerosis Research Center (SPARC) - Robarts Research Institute

London, Ontario, Canada

Site Status

Toronto General Hospital

Toronto, Ontario, Canada

Site Status

Montreal Heart Institute

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017 Sep 14;377(11):1022-1032. doi: 10.1056/NEJMoa1610057.

Reference Type BACKGROUND
PMID: 28902590 (View on PubMed)

Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013 Mar 21;368(12):1092-100. doi: 10.1056/NEJMoa1301440.

Reference Type BACKGROUND
PMID: 23514286 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

G990318

Identifier Type: -

Identifier Source: secondary_id

AGA-006

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

International PFO Consortium
NCT00859885 UNKNOWN
Symptomatic Carotid Outcomes Registry
NCT05300737 ACTIVE_NOT_RECRUITING